Poly MedicureNSE:POLYMED +3.97%90 ROA % is 6.64% as of Mar. 2026, which is 50% below its 10-year median of 13.24. GuruFocus rates NSE:POLYMED with a GF Score™ of 90/100 and a GF Value™ of ₹2,303.01 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 856 Medical Devices & Instruments companies, Poly Medicure ranks better than 84.58% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Poly Medicure's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹2,602 Mil.
Poly Medicure's average Total Assets over the quarter that ended in Mar. 2026 was ₹39,186 Mil. Therefore, Poly Medicure's annualized ROA % for the quarter that ended in Mar. 2026 was 6.64%.
The historical rank and industry rank for Poly Medicure's ROA % or its related term are showing as below:
NSE:POLYMED'
s ROA % Range Over the Past 10 Years
Min: 9 Med: 13.24 Max: 15.03
Current: 9
During the past 13 years, Poly Medicure's highest ROA % was 15.03%. The lowest was 9.00%. And the median was 13.24%.
NSE:POLYMED's ROA % is ranked better than 84.58% of 856
companies
in the Medical Devices & Instruments industry
Industry Median: 0.545
vs NSE:POLYMED: 9.00
Poly Medicure (NSE:POLYMED) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Poly Medicure ROA % Related Terms
Poly Medicure ROA % Historical Data
* Premium members only.
The historical data trend for Poly Medicure's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Poly Medicure's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Poly Medicure ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Poly Medicure's ROA % distribution charts can be found below:
* The bar in red indicates where Poly Medicure's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Poly Medicure (NSE:POLYMED) has a ROA % of 6.64% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Poly Medicure and its competitors. This is 50% below median its historical median of 13.24. Over the past decade, Poly Medicure's ROA % has ranged from 9.00 to 15.03. According to the industry distribution chart, Poly Medicure ranks #132 out of 856 companies in the Medical Devices & Instruments industry, placing it in the top 15.4%.
Is Poly Medicure's ROA % too high?
Poly Medicure's current ROA % of 6.64% is 50% below median its 10-year median of 13.24. Over the past 10 years, this metric has ranged from a low of 9.00 to a high of 15.03. The Medical Devices & Instruments industry median ROA % is 0.55. Poly Medicure's value of 6.64% is 1118.3% above this industry median. Based on the distribution chart, Poly Medicure ranks #132 out of 856 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Poly Medicure has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Poly Medicure's ROA % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Poly Medicure ranks #132 out of 856 companies for ROA %. This places Poly Medicure in the top 15% of its industry — outperforming the majority of peers. The industry median ROA % is 0.55. Poly Medicure's value of 6.64% is 1118.3% above this benchmark. Historically, Poly Medicure's own ROA % has ranged from 9.00 to 15.03 over the past decade. While the company's 10-year median is 13.24 vs. the industry median of 0.55, Poly Medicure has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.55, based on 856 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Poly Medicure's current ROA % of 6.64% is 1118.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Poly Medicure and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Poly Medicure's current ROA % is 6.64%, which is 50% below median its own 10-year median of 13.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poly Medicure stock overvalued right now?
Based on GuruFocus' analysis, Poly Medicure (NSE:POLYMED) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,303.01, compared to a current price of ₹1,732.30 — trading 24.8% below its estimated fair value. The current ROA % is 6.64%, which is 50% below median its 10-year median of 13.24 and 1118.3% above the Medical Devices & Instruments industry median of 0.55. Poly Medicure's overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Poly Medicure (NSE:POLYMED), the current ROA % is 6.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Poly Medicure (NSE:POLYMED) Overvalued in 2026?
Based on GuruFocus' analysis, Poly Medicure stock appears to be undervalued.
The current stock price of ₹1,732.30 is trading 24.8% below its estimated GF Value™ of ₹2,303.01.
GuruFocus considers Poly Medicure to be Modestly Undervalued.
Key valuation signals for NSE:POLYMED:
ROA %: 6.64% (50% below median its 10-year median of 13.24)
GF Value™: ₹2,303.01 vs. price of ₹1,732.30 (24.8% below fair value)
Industry Position: 1118.3% above the Medical Devices & Instruments median (#132 of 856)
No single metric tells the full story. See the NSE:POLYMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Poly Medicure Ltd engages in the manufacturing and sale of medical devices. It offers disposable medical devices for infusion therapy, blood management, gastroenterology, vascular access, surgery and wound drainage, anesthesia, and urology. Some of its products include Ventilator Circuit Combo Kits, Bain Circuits, Safety Introducer Needles, High-Pressure Vaccum Bottle-Triplet, Catheters, and others. Geographically, it derives a majority of its revenue from exports. The company operates under one segment namely Medical Devices.
90GF Score
Get the complete analysis for NSE:POLYMED
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:POLYMED has been successfully added to your 
